The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drugs

Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

July 8, 2019 - 17:05 -- Open Access
Author(s): 
The WorldWide Antimalarial Resistance Network Methodology Study Group
Reference: 
Malaria Journal 2019 18:225, 5 July 2019

Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of persistent, sub-microscopic primary infections.

Medical Treatment: 

NOT Open Access | Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda

March 5, 2019 - 15:56 -- NOT Open Access
Author(s): 
Victor Asua, Joanna Vinden, Melissa D. Conrad, Jennifer Legac, Simon P. Kigozi, Moses R. Kamya, Grant Dorsey, Samuel L. Nsobya and Philip J. Rosenthal
Reference: 
Antimicrob. Agents Chemother. February 2019 63:e01818-18

The potential spread of antimalarial drug resistance to Africa, in particular for artemisinins and key partner drugs, is a major concern.

Country: 
Medical Treatment: 

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial

October 30, 2018 - 12:49 -- Open Access
Author(s): 
Nilay Thakkar, Justin A. Green, Gavin C. K. W. Koh, Stephan Duparc, David Tenero and Navin Goyal
Reference: 
Antimicrob. Agents Chemother. November 2018 62:e00711-18

Tafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acute Plasmodium vivax malaria, which is the first new treatment in almost 60 years.

Medical Treatment: 

Characterizing Blood-Stage Antimalarial Drug MIC Values In Vivo Using Reinfection Patterns

July 3, 2018 - 16:24 -- Open Access
Tags: 
Author(s): 
James Watson, Cindy S. Chu, Joel Tarning and Nicholas J. White
Reference: 
Antimicrob. Agents Chemother. July 2018 vol. 62 no. 7 e02476-17

The MIC is an essential quantitative measure of the asexual blood-stage effect of an antimalarial drug.

Medical Treatment: 

NOT Open Access | Drug targeting of one or more aminoacyl-tRNA synthetase in the malaria parasite Plasmodium falciparum

June 19, 2018 - 14:52 -- NOT Open Access
Author(s): 
Yogavel Manickam, Rini Chaturvedi, Palak Babbar, Nipun Malhotra, Vitul Jain, Amit Sharma
Reference: 
Drug Discovery Today, Volume 23, Issue 6, June 2018, Pages 1233-1240

Malaria remains a major infectious disease and, despite incidence reduction, it threatens resurgence in drug-resistant forms.

Medical Treatment: 

A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China

April 4, 2018 - 14:56 -- Open Access
Tags: 
Author(s): 
Yangmu Huang, Ke Pan, Danlu Peng and Andy Stergachis
Reference: 
Malaria Journal 2018 17:149, 3 April 2018

Government support, as well as innovative incentives and collaboration mechanisms are needed for further adoption of WHO PQ for anti-malarial drugs in China.

Medical Treatment: 

NOT Open Access | Inactivation of Plasmepsins 2 and 3 Sensitizes Plasmodium falciparum to the Antimalarial Drug Piperaquine

March 28, 2018 - 15:36 -- NOT Open Access
Author(s): 
Angana Mukherjee, Dominic Gagnon, Dyann F. Wirth and Dave Richard
Reference: 
Antimicrob. Agents Chemother. April 2018 vol. 62 no. 4 e02309-17

Dihydroartemisinin-piperaquine (DHA-PPQ), the current frontline artemisinin combination therapy used to treat Plasmodium falciparum malaria in multiple Southeast Asian countries, is now increasingly failing in Cambodia, where artemisinin resistance is nearly fixed, which suggests that PPQ resistance has emerged and is spreading rapidly in the Greater Mekong Subregion.

Medical Condition: 
Medical Treatment: 

Functional interrogation of Plasmodium genus metabolism identifies species- and stage-specific differences in nutrient essentiality and drug targeting

January 8, 2018 - 16:03 -- Open Access
Tags: 
Author(s): 
Alyaa M. Abdel-Haleem, Hooman Hefzi, Katsuhiko Mineta, Xin Gao, Takashi Gojobori, Bernhard O. Palsson, Nathan E. Lewis, Neema Jamshidi
Reference: 
PLoS Comput Biol 14(1): e1005895

Several antimalarial drugs exist, but differences between life cycle stages among malaria species pose challenges for developing more effective therapies.

Medical Treatment: 

Collection Reviews: malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication

December 7, 2017 - 15:28 -- Open Access
Author(s): 
The malERA Refresh Consultative Panel on Insecticide and Drug Resistance
Reference: 
PLoS Med 14(11): e1002450

Resistance to first-line treatments for Plasmodium falciparum malaria and the insecticides used for Anopheles vector control are threatening malaria elimination efforts.

Medical Treatment: 

Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein

November 30, 2017 - 14:50 -- Open Access
Author(s): 
David Oyen, Jonathan L. Torres, Ian A. Wilson, et al.
Reference: 
PNAS November 28, 2017 vol. 114 no. 48 E10438-E10445

Acquired resistance against antimalarial drugs has further increased the need for an effective malaria vaccine.

Medical Treatment: 

Pages

Subscribe to RSS - antimalarial drugs